Rapidly progressive glomerulonephritis treated with anticoagulants.
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000097:blood / Q000378:metabolism; D004176:Dipyridamole / Q000627:therapeutic use; D004231:Diuresis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005455:Fluorescent Antibody Technique; D005921:Glomerulonephritis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000473:pathology; D008875:Middle Aged; D010630:Phenindione / Q000627:therapeutic use; D011241:Prednisone / Q000009:adverse effects; D011507:Proteinuria; D013442:Sulfinpyrazone / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010630:Phenindione; D014859:Warfarin; D004176:Dipyridamole; D006493:Heparin; D003404:Creatinine; D001379:Azathioprine; D013442:Sulfinpyrazone; D011241:Prednisone